Semaglutide for MASH: Can Wegovy Treat Fatty Liver Disease in 2026?

Quick answer: Can semaglutide treat MASH?

Semaglutide is emerging as a promising treatment for MASH (metabolic dysfunction-associated steatohepatitis), the progressive form of fatty liver disease. While not yet specifically FDA-approved for MASH, clinical trials — including the ESSENCE trial — show that semaglutide can achieve MASH resolution in a significant percentage of patients, reduce liver fat, and improve liver enzymes. For patients with MASH who also have obesity or type 2 diabetes, semaglutide addresses both conditions simultaneously. Tirzepatide is also being studied for MASH with promising early results.

What is MASH?

MASH (metabolic dysfunction-associated steatohepatitis) is the updated name for NASH (non-alcoholic steatohepatitis). The name was changed in 2023 to reflect the metabolic origins of the disease. MASH is a progressive liver condition characterized by:

• Fat accumulation in the liver (steatosis)
• Liver inflammation (hepatitis)
• Liver cell damage
• Potential progression to fibrosis, cirrhosis, and liver failure

MASH is closely linked to obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. It affects an estimated 5% of US adults and is one of the leading causes of liver transplantation.

How semaglutide helps with MASH

Semaglutide addresses MASH through multiple mechanisms:

• Weight loss — The primary driver. Losing 10% or more of body weight is associated with MASH resolution and fibrosis improvement
• Insulin sensitivity — Improved insulin resistance reduces hepatic fat accumulation
• Anti-inflammatory effects — GLP-1 receptor agonists reduce systemic inflammation, which may reduce liver inflammation
• Direct hepatic effects — GLP-1 receptors are present in the liver, and semaglutide may have direct protective effects on hepatocytes
• Reduced de novo lipogenesis — Semaglutide may reduce the liver's production of new fat

Clinical trial results: ESSENCE and beyond

The ESSENCE trial (Novo Nordisk) is the landmark study evaluating semaglutide for MASH. Key findings:

• MASH resolution — A significant percentage of patients achieved MASH resolution without worsening of fibrosis
• Liver fat reduction — Measurable reduction in hepatic fat fraction on imaging
• Liver enzyme improvement — ALT and AST levels improved in treated patients
• Fibrosis — Fibrosis improvement was less consistent than MASH resolution, suggesting that advanced fibrosis may require additional therapies
• Weight loss correlation — Patients who achieved greater weight loss had better MASH outcomes

See our GLP-1 and fatty liver guidefor more on GLP-1s and liver disease.

Semaglutide vs other MASH treatments

Tirzepatide for MASH

Tirzepatide is also being studied for MASH in the SURMOUNT-MASH trial. Early data suggests tirzepatide may achieve even greater liver fat reduction than semaglutide, due to its dual GIP/GLP-1 mechanism and greater weight loss (up to 22.5% vs 15% for semaglutide). See our tirzepatide guideand GLP-1 + SGLT2 guide.

GLP-1 and SGLT2 combination for MASLD/MASH

The American Diabetes Association (ADA) now recommends combining GLP-1 receptor agonists with SGLT2 inhibitors (like Jardiance/empagliflozin) for patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The combination provides synergistic effects: GLP-1s drive weight loss and reduce liver fat, while SGLT2 inhibitors improve insulin sensitivity and reduce hepatic glucose production. See our GLP-1 + SGLT2 guide.

Who should consider semaglutide for MASH?

• Patients with MASH confirmed by biopsy or non-invasive testing
• Patients with MASH and obesity (BMI 30+) — semaglutide addresses both conditions
• Patients with MASH and type 2 diabetes — semaglutide improves blood sugar and liver health
• Patients who have not responded to lifestyle changes alone
• Patients with early-to-moderate fibrosis (F0-F2) — best outcomes

How to get semaglutide for MASH

If you have MASH and want to explore semaglutide:

1. Talk to your hepatologist or primary care provider — Discuss whether semaglutide is appropriate for your liver condition
2. Get a prescription — If you meet BMI criteria (30+, or 27+ with a weight-related condition), your provider can prescribe Wegovy
3. Fill the prescription — Use NovoCare ($199 to $399/mo), insurance + savings card ($25/mo), or compounded semaglutide ($149 to $299/mo). See our semaglutide near me guide
4. Monitor liver enzymes — Regular blood work to track ALT, AST, and liver function
5. Track progress — Follow-up imaging or FibroScan to assess liver fat and fibrosis

FAQ

Related articles

• GLP-1 and Fatty Liver: Can Semaglutide Treat MASH/NASH?
• GLP-1 and SGLT2 Inhibitors: Combination Therapy
• GLP-1 for Metabolic Syndrome
• GLP-1 and Inflammation
• Semaglutide Near Me
• GLP-1 and Heart Health
• GLP-1 for Non-Diabetics